Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Teneriello, Michael; Tseng, Paul C.; Crozier, Mark; Encarnacion, Carlos A.; Hancock, Kenneth C.; Messing, Mark J.; Boehm, Kristi A.; Williams, Alicia; Asmar, Lina

doi:10.1200/jco.2008.18.9548

Cited by 72 publications

(35 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This new formulation was approved by the Food and Drug Administration (FDA) for clinical use in February 2007. Encouraging Phase I and II clinical studies have been published for solid tumours as well as for non-small cell lung cancer (28) and recurrent ovarian, peritoneal, or fallopian tube cancer (29).…”

Section: Introductionmentioning

confidence: 99%

Toxicological Study and Efficacy of Blank and Paclitaxel-Loaded Lipid Nanocapsules After i.v. Administration in Mice

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Toxicological Study and Efficacy of Blank and Paclitaxel-Loaded Lipid Nanocapsules After i.v. Administration in Mice

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In this group of 22 patients with advanced-stage disease, the ORR was 50% (27% CR and 23% PR rates). In a single-agent phase II study, 44 evaluable patients were treated with nab-paclitaxel 260 mg/m 2 intravenously over 30 minutes every 21 days for 6 cycles or progression [15] with ORR of 64 and median PFS of 8.5 months. Severe adverse events were infrequent despite the dose, including 11% grade 4 neutropenia, 2% grade 3 fatigues and 13% grade 2-3 neuropathy.…”

Section: Results: 17 Patients Discussionmentioning

confidence: 99%

Nab-Paclitaxel in Recurrent Ovarian Cancer: An Institution Based Retrospective Study

Singh¹,

Pankaj²,

Kota³

et al. 2015

JCR

View full text Add to dashboard Cite

Abstract:Introduction: Nab-paclitaxel is a novel cremophor free nanoparticle of albumin-stabilized paclitaxel. We evaluated the efficacy and toxicity of the nab-paclitaxel in recurrent ovarian cancer patients. Methods: 17 patients of recurrent epithelial ovarian cancer with platinum and taxane resistance defined by persistent or progressive disease following recurrence within six months of treatment completion and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) or elevated CA-125 (≥ 70 U/ mL) in patients without measurable disease were included in trial. Patients were treated with nab-paclitaxel for six cycles or until disease progression. Results: Median age of patients was 62 years; 76% of patients had stage IIIC or IV disease, 82% had Eastern Cooperative Oncology Group performance status of 0, and 88% had prior surgery. For assessable patients, the objective response rate (ORR) was 58% (6 complete responses [CR] and 4 partial responses [PR] among 17 assessable patients). In patients evaluated with RECIST only, the ORR was 44.4% (one CR and three PR of 9 patients). In patients with only elevated CA-125, ORR was 75% (5 CRs and 1 PRs of 8 patients). Median time to response was 1.3 months (range 0.5 to 4.8 months). Estimated median progression-free survival was 8.5 months. The most frequent grade 3 to 4 treatment-related toxicities were neutropenia (35%) and neuropathy (11%). Conclusion: Nab-paclitaxel as a single agent in patients with recurrent epithelial ovarian cancer seems to be well tolerated and effective in patients who are previously treated with paclitaxel or platins.

show abstract

“…In order to circumvent the development of paclitaxel resistance, inhibition of SFKs with its inhibitors such as dasatinib should also been tested in combination with novel taxanes such as the Epothilones, 81 Larotaxel (RPR 109881A), 169 and nanoparticle albumin-bound (nab)-paclitaxel. 170 In addition, identification of the biomarkers that can predict SFK inhibition-enhanced paclitaxel effect would permit personalization of combined therapy with SFK inhibition and paclitaxel.…”

Section: Discussionmentioning

confidence: 99%

Src family kinases and paclitaxel sensitivity

Bast

2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Src-family Kinases (SFKs) participate in the regulation of proliferation, differentiation, apoptosis, autophagy, adhesion, migration, invasion and angiogenesis in normal and cancer cells. Abnormal expression of SFKs has been documented in cancers that arise in breast, colon, ovary, melanocyte, gastric mucosa, head and neck, pancreas, lung and brain. Targeting SFKs in cancer cells has been shown to be a promising therapeutic strategy in solid tumors, particularly in ovarian, colon and breast cancers. Paclitaxel is one of most widely used chemotherapeutic agents for the management of ovarian, breast, lung and head and neck cancers. As a microtubulestabilizing agent, paclitaxel possesses both mitosis-dependent and mitosis-independent activities against cancer cells. A variety of mechanisms such as deregulation of P-glycoprotein, alteration of tubulin isotypes, alteration of microtubuleregulatory proteins, deregulation of apoptotic signaling pathways, mutation of tubulins and overexpression of copper transporters have been implicated in the development of primary or secondary resistance to paclitaxel. By affecting cancer cell survival, proliferation, autophagy, microtubule stability, motility, and/or angiogenesis, SFKs interact with mechanisms that regulate paclitaxel sensitivity. inhibition of SFKs can potentiate the anti-tumor activity of paclitaxel by enhancing apoptosis, autophagy and microtubule stability. Based on pre-clinical observations, administration of SFK

show abstract

Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Abstract: Nab-paclitaxel is active in this group of patients with recurrent ovarian, peritoneal, or fallopian tube cancer. The ORR was 64%. Toxicities were manageable. Further studies of nab-paclitaxel in combination with platinum are warranted.

Cited by 72 publications

References 17 publications

Toxicological Study and Efficacy of Blank and Paclitaxel-Loaded Lipid Nanocapsules After i.v. Administration in Mice

Toxicological Study and Efficacy of Blank and Paclitaxel-Loaded Lipid Nanocapsules After i.v. Administration in Mice

Nab-Paclitaxel in Recurrent Ovarian Cancer: An Institution Based Retrospective Study

Src family kinases and paclitaxel sensitivity

Contact Info

Product

Resources

About